The evolution of dual antiplatelet therapy in the setting of acute coronary syndrome: Ticagrelor versus clopidogrel

Postgraduate Medicine

Volumn 128, Issue 2, 2016, Pages 159-163

  Amico, Frank ^a   Amico, Angela ^b   Mazzoni, Jennifer ^a   Moshiyakhov, Mark ^a   Tamparo, William ^c  

^a Deborah Heart and Lung   (United States)

^b ST JOHN'S UNIVERSITY   (United States)

^c NEW YORK HOSPITAL QUEENS   (United States)

Author keywords

Acute coronary syndrome; PLATO trial; STEMI; Ticagrelor

Indexed keywords

ACETYLSALICYLIC ACID; CLOPIDOGREL; PLACEBO; TICAGRELOR; ADENOSINE; ANTITHROMBOCYTIC AGENT; PURINERGIC P2 RECEPTOR ANTAGONIST; TICLOPIDINE;

ACUTE CORONARY SYNDROME; ADULT; ARTICLE; BLEEDING; COMBINATION CHEMOTHERAPY; CONTROLLED STUDY; CORONARY ARTERY BYPASS GRAFT; CORONARY ARTERY BYPASS GRAFT RELATED BLEEDING; DRUG EFFICACY; DRUG SAFETY; DYSPNEA; HUMAN; LOADING DRUG DOSE; MAJOR CLINICAL STUDY; MULTICENTER STUDY; OUTCOME ASSESSMENT; RANDOMIZED CONTROLLED TRIAL; SMOKING; TREATMENT OUTCOME; ANALOGS AND DERIVATIVES; FEMALE; MALE;

ACUTE CORONARY SYNDROME; ADENOSINE; FEMALE; HUMANS; MALE; PLATELET AGGREGATION INHIBITORS; PURINERGIC P2 RECEPTOR ANTAGONISTS; TICLOPIDINE;

EID: 84964040073     PISSN: 00325481     EISSN: 19419260     Source Type: Journal    
DOI: 10.1080/00325481.2016.1118351     Document Type: Article

References (11)

1. Wallentin L, Becker RC, Budaj A, et al. Ticagrelor versus clopidogrel in patients with acute coronary syndromes. N Eng J Med. 2009;361(11):1045-1057.
2. Gurbel PA, Bliden KP, Butler K, et al. Randomized doubleblind assessment of the ONSET and OFFSET of the antiplatelet effects of ticagrelor versus clopidogrel in patients with stable coronary artery disease. The ONSET/ OFFSET study. Circulation. 2009;120(25):2577-2585.
3. Brilinta, US full prescribing information, December 2013. [cited 2014 Jan 22]. Available from: http://www.azpicen tral.com/brilinta/brilinta.pdf#page=1.
4. Effient, US full prescribing information, November 2013. [cited 2014 Jan 22]. Available from: http://pi.lilly.com/us/ effient.pdf.
5. Plavix PI, US full prescribing information, December 2013. [cited 2014 Jan 22]. Available from: http://packageinserts. bms.com/pi/pi_plavix.pdf.
6. Amsterdam EA, Wenger NK, Brindis RG, et al. 2014 AHA/ ACC guideline for the management of patients with non-ST-elevation acute coronary syndromes a report of the American college of cardiology/American heart association task force on practice guidelines. J Am Coll Cardiol. 2014;64(24):e139-228.
7. O'Gara PT, Kushner FG, Ascheim DD, et al. 2013 ACCF/ AHA guideline for the management of ST-elevation myocardial infarction: executive summary: a report of the American College of Cardiology Foundation/ American Heart Association Task Force on Practice Guidelines: developed in collaboration with the American College of Emergency Physicians and Society for Cardiovascular Angiography and Interventions. Circulation. 2013;127(4):529-555.
8. Smith SC Jr, Benjamin EJ, Bonow RO, et al. World Heart Federation and the Preventive Cardiovascular Nurses Association. AHA/ACCF secondary prevention and risk reduction therapy for patients with coronary and other atherosclerotic vascular disease: 2011 update: a guideline from the American Heart Association and American College of Cardiology Foundation. Circulation. 2011;124 (22):2458-2473.
9. Wiviott SD, Braunwald E, McCabe CH, et al. Prasugrel versus clopidogrel in patients with acute coronary syndromes. NEJM. 2007;357:2001-2015.
10. Nylander S, Femia E, Scavone M, et al. Ticagrelor inhibits human platelet aggregation via adenosine in addition to P2Y12 antagonism. J Thromb Haenost. 2013;11:1867-1876.
11. Bonaca MP, Bhatt DL, Cohen M, et al. Long-term use of ticagrelor in patients with prior myocardial infarction. N Eng J Med. 2015;372(19):1791-1800.